We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort.
- Authors
Nannini, Simon; Guisier, Florian; Curcio, Hubert; Ricordel, Charles; Demontrond, Pierre; Abdallahoui, Safa; Baloglu, Seyyid; Greillier, Laurent; Chouaid, Christos; Schott, Roland
- Abstract
Non-small cell lung cancer (NSCLC) is the most common cause of brain metastasis (BM). Little is known about immune checkpoint inhibitor activity in the central nervous system, especially in patients receiving monotherapy for tumors with a tumor proportion score (TPS) ≥ 50%. This noninterventional, retrospective, multicenter study, conducted with the GFPC, included treatment-naïve patients strongly positive for PD-L1 (TPS ≥ 50%) with BM receiving first-line single-agent pembrolizumab treatment between May 2017 and November 2019. The primary endpoints were centrally reviewed intracranial overall response rates (ORRs), centrally reviewed intracranial progression-free survival (cPFS), extracranial PFS, and overall survival were secondary endpoints. Forty-three patients from five centers were included. Surgical or local radiation therapy was administered to 31 (72%) patients, mostly before initiating ICI therapy (25/31). Among 38/43 (88.4%) evaluable patients, the intracranial ORR was 73%. The median PFS was 8.3 months. The cerebral and extracerebral median PFS times were 9.2 and 5.3 months, respectively. The median OS was 25.5 months. According to multivariate analysis, BM surgery before ICI therapy was the only factor significantly associated with both improved PFS (HR = 0.44) and OS (HR = 0.45). This study revealed the feasibility and outcome of front-line pembrolizumab treatment in this population with BM.
- Subjects
NON-small-cell lung carcinoma; BRAIN metastasis; STEREOTACTIC radiosurgery; IMMUNOTHERAPY; METASTASIS; BRAIN cancer; IMMUNE checkpoint inhibitors
- Publication
Current Oncology, 2024, Vol 31, Issue 3, p1656
- ISSN
1198-0052
- Publication type
Article
- DOI
10.3390/curroncol31030126